Mitochondrially Dysfunctional Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Mitochondrially-dysfunctional neurons are neurons exhibiting impaired mitochondrial function, which represents a hallmark of nearly all neurodegenerative diseases. These neurons demonstrate characteristic deficits in energy production, increased oxidative stress, defective quality control mechanisms, and disrupted calcium homeostasis[1]. Mitochondrial dysfunction precedes clinical symptoms and drives disease progression in conditions including Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Huntington's disease.
Mitochondrially-dysfunctional neurons exhibit severe energy impairment[2]:
Accumulation of oxidative damage characterizes these neurons:
The mitophagy and mitochondrial dynamics machinery is compromised:
Mitochondrial DNA (mtDNA) is particularly vulnerable[3]:
Mitochondrial calcium handling is compromised:
| Process | Normal Function | Dysfunctional State |
|---|---|---|
| Fusion | Mfn1/2, OPA1-mediated | Reduced fusion |
| Fission | Drp1-mediated | Increased fission |
| Biogenesis | PGC-1α driven | Impaired biogenesis |
| Mitophagy | Parkin, PINK1 | Defective clearance |
The cellular response to mtDNA damage includes:
Mitochondrial dysfunction in AD is extensive[4]:
Amyloid-beta → Mitochondrial accumulation → ROS generation →
Protein oxidation → Electron transport impairment → Energy failure →
Synaptic loss → Neuronal death
PD shows distinctive mitochondrial patterns[5]:
ALS exhibits mitochondrial failure[6]:
HD features mitochondrial impairment[7]:
| Compound | Target | Disease Stage |
|---|---|---|
| CoQ10 | Electron transport chain | PD, AD |
| MitoQ | Antioxidant | Early PD |
| MitoTEMPO | ROS scavenging | Research |
| Rapamycin | Mitophagy activation | Preclinical |
| Edaravone | Oxidative stress | ALS (approved) |
Emerging therapeutic modalities include:
Lin MT, Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. Nature. 2006
Van Laar VS, Berman SB. Mitochondrial dynamics in Parkinson's disease. Exp Neurol. 2009
Wallace DC. Mitochondrial diseases in man and mouse. Science. 1999
Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic loss. Trends Neurosci. 2008
Johri A, Beal MF. Mitochondrial targeting for neurodegeneration. Biochem Pharmacol. 2012
Kim J, et al. Mitochondrial dysfunction in ALS. Nat Rev Neurol. 2018
Cui L, et al. Mitochondrial dysfunction in Huntington's disease. Biochim Biophys Acta. 2010
Mitochondrially Dysfunctional Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Mitochondrially Dysfunctional Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Lin MT, Beal MF. (2006). Mitochondrial dysfunction in neurodegenerative diseases. Nature, 443(7113), 787-795. https://doi.org/10.1038/nature05292 ↩︎
Van Laar VS, Berman SB. (2009). Mitochondrial dynamics in Parkinson's disease. Experimental Neurology, 218(2), 247-256. ↩︎
Wallace DC. (1999). Mitochondrial diseases in man and mouse. Science, 283(5407), 1482-1488. ↩︎
Reddy PH, Beal MF. (2008). Amyloid beta, mitochondrial dysfunction and synaptic loss: pathogenic pathways in Alzheimer's disease. Trends in Neurosciences, 31(9), 454-463. ↩︎
Schapira AH. (2008). Mitochondria in the etiology and pathogenesis of Parkinson's disease. Lancet Neurology, 7(1), 97-109. ↩︎
Kim J, et al. (2018). Mitochondrial dysfunction in the pathogenesis of ALS. Nature Reviews Neurology, 14(4), 215-230. ↩︎
Cui L, et al. (2010). Mitochondrial dysfunction in Huntington's disease. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1802(1), 62-67. ↩︎